Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy

Journal of General Internal Medicine

Volumn 22, Issue 9, 2007, Pages 1305-1310

  Yee, Ellen F T ^a,c   White, Robert E ^b   Murata, Glen H ^a,c   Handanos, Christine ^a,c   Hoffman, Richard M ^a,c  

^a NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^b LOVELACE CLINIC FOUNDATION   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen deprivation therapy; DXA scan; Osteoporosis; Prevention; Prostate cancer; Screening

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; PHENYTOIN; PROSTATE SPECIFIC ANTIGEN; THYROID HORMONE; VITAMIN D;

AGED; ALCOHOL CONSUMPTION; ARTICLE; BONE METASTASIS; CANCER STAGING; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DIABETES MELLITUS; DUAL ENERGY X RAY ABSORPTIOMETRY; ETHNICITY; FRACTURE; GLEASON SCORE; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; ORCHIECTOMY; OSTEOPOROSIS; PATIENT CARE; PRESCRIPTION; PROSTATE CANCER; RACE DIFFERENCE; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING;

AGED; ANDROGENS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISEASE MANAGEMENT; HORMONE ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSTATIC NEOPLASMS;

EID: 34547838433     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-007-0291-4     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56:106-30.
2. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238-44.
3. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141-9.
4. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology. 2002;60(Suppl 3A):7-12.
5. Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167:2361-7.
6. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163:181-6.
7. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer. 1998;83:1561-6.
8. Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer. 2001;92:1444-50.
9. Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int. 1995;57:97-9.
10. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87:3656-61.
11. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008-12.
12. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948-55.
13. Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int. 2005;16:707-11.
14. Oefelein MG, Ricchuiti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001;166:1724-8.
15. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006;175:136-9.
16. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897-903.
17. Melton LJ, 3rd, Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zincke H. Fracture risk following bilateral orchiectomy. J Urol. 2003;169:1747-50.
18. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353:878-82.
19. Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med. 2002;162:2217-22.
20. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168:1005-7.
21. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004;100:892-9.
22. Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am. 2004;31:331-52.
23. Smith MR. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer. 2003;97(3 Suppl):789-95.
24. Bae DC, Stein BS. The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate. J Urol. 2004;172:2137-44.
25. Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer. 2005;103:237-41.
26. Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum. 2002;46:3136-42.
27. Solomon DH, Finkelstein JS, Katz JN, Mogun H, Avorn J. Underuse of osteoporosis medications in elderly patients with fractures. Am J Med. 2003;115:398-400.
28. Feldstein A, Elmer PJ, Orwoll E, Herson M, Hillier T. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med. 2003;163:2165-72.
29. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158:1789-95.
30. Krupski TL, Smith MR, Lee WC, et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer. 2004;101:541-9.
31. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-64.
32. Morris CA, Cabral D, Cheng H, et al. Patterns of bone mineral density testing: current guidelines, testing rates, and interventions. J Gen Intern Med. 2004;19:783-90.
33. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167(10 Suppl):S1-34.
34. Writing Group for the ISCD Position Development Conference. Indications and reporting for dual-energy x-ray absorptiometry. J Clin Densitom. 2004;7:37-44.
35. Mauck KF, Clarke BL. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc. 2006;81:662-72.
36. Gourlay M, Richy F, Reginster JY. Strategies for the prevention of hip fracture. Am J Med. 2003;115:309-17.
37. Solomon DH, Connelly MT, Rosen CJ, et al. Factors related to the use of bone densitometry: survey responses of 494 primary care physicians in New England. Osteoporos Int. 2003;14:123-9.
38. Simonelli C, Killeen K, Mehle S, Swanson L. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc. 2002;77:334-8.
39. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604-10.
40. Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int. 2004;24:110-3.
41. Saad F, Gleason DM, Murray R, et al., Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-68.
42. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007;146:416-24.
43. Mazanec D. Osteoporosis screening: time to take responsibility. Arch Intern Med. 2004;164:1047-8.
44. Field MH. Fractures, osteoporosis, and the endocrinologist. Arch Intern Med. 2003;163:2796.
45. Kiebzak GM. Fractures, osteoporosis, and the endocrinologist. In reply. Arch Intern Med. 2003;163:2796-7.
46. Braga-Basaria M, Basaria S. Preventing skeletal complications in androgen deprived men with prostate cancer: time for action. J Endocrinol Invest. 2006;29:467-70.
47. Gourlay M. Osteoporosis management: out of subspecialty practice and into primary care. Am Fam Phys. 2004;70:1219-20.
48. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448-56.
49. Cuddihy MT, Amadio PC, Melton LJ 3rd. Patient barriers to osteoporosis interventions after fracture. Mayo Clin Proc. 2002;77:875.
50. Backett-Milburn K, Parry O, Mauthner N. 'I'll worry about that when it comes along': osteoporosis, a meaningful issue for women at mid-life? Health Educ Res. 2000;15:153-62.